248 related articles for article (PubMed ID: 18980045)
1. YAZ in the treatment of premenstrual dysphoric disorder.
Rapkin AJ
J Reprod Med; 2008 Sep; 53(9 Suppl):729-41. PubMed ID: 18980045
[TBL] [Abstract][Full Text] [Related]
2. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein AA; Helmerhorst FM
Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
[TBL] [Abstract][Full Text] [Related]
4. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
Fenton C; Wellington K; Moen MD; Robinson DM
Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein AA; Helmerhorst FM
Cochrane Database Syst Rev; 2009 Apr; (2):CD006586. PubMed ID: 19370644
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein A; Helmerhorst FM
Cochrane Database Syst Rev; 2008 Jan; (1):CD006586. PubMed ID: 18254106
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone/ethinyl estradiol.
Rapkin AJ; Sorger SN; Winer SA
Drugs Today (Barc); 2008 Feb; 44(2):133-45. PubMed ID: 18389090
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives containing drospirenone for premenstrual syndrome.
Ma S; Song SJ
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD006586. PubMed ID: 37365881
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
12. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
Marr J; Heinemann K; Kunz M; Rapkin A
Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
[TBL] [Abstract][Full Text] [Related]
13. [Premenstrual dysphoric disorder (PMDD): Drug and psychotherapeutique management, a literature review].
Marais-Thomas H; Chapelle F; de Vaux-Boitouzet V; Bouvet C
Encephale; 2024 Apr; 50(2):211-232. PubMed ID: 37821319
[TBL] [Abstract][Full Text] [Related]
14. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
Svojanovská K
Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
[TBL] [Abstract][Full Text] [Related]
15. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder.
Rapkin A
Psychoneuroendocrinology; 2003 Aug; 28 Suppl 3():39-53. PubMed ID: 12892989
[TBL] [Abstract][Full Text] [Related]
16. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
18. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
[TBL] [Abstract][Full Text] [Related]
20. Drospirenone: a novel progestin.
Rapkin AJ; Winer SA
Expert Opin Pharmacother; 2007 May; 8(7):989-99. PubMed ID: 17472544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
